Skip to main content

Desmopressin

Desmopressin (DDAVP) is a synthetic vasopressin V2-receptor agonist with three established urologic uses: (1) nocturia from nocturnal polyuria in adults, its principal indication; (2) primary monosymptomatic nocturnal enuresis in children; and (3) perioperative hemostasis in patients with mild hemophilia A or von Willebrand disease Type I undergoing urologic surgery. It is the only antidiuretic agent specifically indicated for nocturia due to nocturnal polyuria, but use is gated by the risk of hyponatremia, a class effect with formulation-specific boxed warnings.[2][3][5] In a matched cohort of 3,137 adults older than 50 newly prescribed an older desmopressin formulation and 3,137 oxybutynin users, the rate of primary-position hyponatremia diagnosis was 13-fold higher with desmopressin (HR 13.19).[21]

For the broader nocturia evaluation framework, see Nocturia. For the storage-OAB pharmacology landing, see Storage / OAB.

Pharmacology​

Mechanism​

Desmopressin is a modified vasopressin analogue (deaminated cysteine-1, D-arginine-8) that yields:[5]

  • Selective V2 agonism in the renal collecting duct leads to aquaporin-2 trafficking to the apical membrane, free-water reabsorption and reduced urine production
  • Markedly decreased V1 (vascular) activity. Clinically antidiuretic doses are below the vasopressor threshold
  • Hemostatic effect. Increases circulating von Willebrand factor (vWF) and factor VIII activity; response varies and must be established for the bleeding disorder
  • Prolonged action versus native AVP. The DDAVP oral tablet has a plasma half-life of 1.5–2.5 h and an antidiuretic effect lasting up to 8 h at usual CDI doses; after injection, the factor VIII hemostatic effect lasts about 8–12 h.[5][6]

Pharmacokinetics by formulation​

FormulationOnsetNotes
Oral tabletAntidiuretic onset ~1 h; peak 4–7 hBioavailability 0.08–0.16%[6][35]
Sublingual tablet (Nocdurna; Noqdirna in the EU/UK)Sublingual absorptionTaken without water; bypasses nasal congestion and GI transit[3]
Intranasal sprayPeak ~1.5 hPostmarketing reports found more hyponatremia and hyponatremic convulsions with nasal spray than tablets for enuresis; nasal spray is not indicated for primary nocturnal enuresis.[33]
IV / SC injectionMinutesHemostasis and central DI; the CDI injection dose is approximately 1/10th the intranasal maintenance dose, with individual reassessment[5]

Formulations — doses are not interchangeable​

FormulationBrandsDose rangePrimary urologic indication
Oral tabletGeneric, DDAVP (0.1 and 0.2 mg tablets)CDI 0.1–1.2 mg/day in divided doses; enuresis 0.2–0.6 mg at bedtimeCDI, primary nocturnal enuresis, off-label nocturia[6]
Sublingual tablet (NOCDURNA)27.7 / 55.3 µg desmopressin acetateWomen 27.7 µg; men 55.3 µg, 1 h before bedAdults with NP and ≥2 nocturnal voids; equivalent to 25 / 50 µg desmopressin free base. The cited Antares US NDCs list May 31, 2025 as their marketing end date; the same 25 / 50 µg strengths remain licensed in Europe/UK as Noqdirna[3][27][28]
Low-dose intranasal (NOCTIVA; historical US label)0.83 / 1.66 µg desmopressin acetate per sprayAge/risk-based, not sex-based; ≥65 yr or increased hyponatremia risk starts at 0.83 µgAdults with NP and ≥2 nocturnal voids; no longer marketed in the US (Avadel stopped marketing it in 2019); label information here is historical[23][29]
Standard intranasal sprayDDAVP NS / genericAdults with CDI: 10–40 µg/day (10 µg per spray), individualizedCDI; not indicated for primary nocturnal enuresis[33]
IV / SCDDAVP Injection0.3 µg/kg IV (max 20 µg) for hemostasis; CDI uses a separate regimen belowHemophilia A, vWD Type I, CDI[5][6]

Urologic Applications​

1. Nocturia from nocturnal polyuria (adults)​

The dominant urologic use. Nocturnal polyuria, defined as nocturnal urine production exceeding 20–33% of 24-hour output (age-dependent), can arise from several causes, including altered nocturnal AVP secretion, sleep apnea and fluid redistribution.[1] Desmopressin reduces urine production.[1]

Efficacy.

  • The Cochrane review included 14 RCTs (2,966 men) across five comparisons; its 3–12-month desmopressin-versus-placebo estimate came from one trial (115 men: MD −0.85 nocturnal voids/night, 95% CI −1.17 to −0.53; low-quality evidence).[4] At ≤3 months, the Cochrane estimate was MD −0.61 (six trials, 1,982 men; 95% CI −0.96 to −0.27), whereas the related BJU report gave MD −0.46 (95% CI −0.94 to 0.01).[4][9]
  • A systematic review of 10 RCTs (2,191 patients) found a 100 µg dose provided about 1 additional hour of undisturbed sleep before the first void and 0.72 fewer voids per night versus placebo.[10]
  • In the three-month NOCDURNA registration trials, the sex-specific sublingual doses produced placebo-adjusted reductions of 0.3 nocturnal voids per night in women (118 treated; 114 placebo; 95% CI 0.1–0.5 fewer) and 0.4 in men (102 treated; 128 placebo; 95% CI 0.2–0.6 fewer).[3] Older oral-dose studies suggest a larger effect in men with documented NP and at higher doses.[4][9]
  • Desmopressin has a similar effect on nocturnal voids as alpha-blockers (MD 0.30, 95% CI −0.20 to 0.80; moderate quality), and adding desmopressin to an alpha-blocker yields only a small, likely unimportant additional reduction.[9]
  • In an observational cohort of older men (60–95 yr) prescribed 0.1 mg oral desmopressin tablets, with a half-tablet starting dose used when warranted, paired one-month data from 126 men under 80 and 56 men aged 80 or older showed median reductions of 2 and 3 voids/night, 705 and 660 mL in nocturnal urine volume, and 1 and 2 h more undisturbed sleep, respectively; 70.1% of the 234 enrolled men continued treatment for 3 months, and 39/234 (16.7%) discontinued for hyponatremia detected on monitoring.[11]

Sex-specific dosing (Nocdurna sublingual tablet; FDA-approved 2018, not currently marketed in the US):[3][36]

NOCDURNA is not recommended for nocturia during pregnancy.[3]

PatientDose
Women27.7 µg desmopressin acetate (=25 µg desmopressin), SL 1 h before bed[3]
Men55.3 µg desmopressin acetate (=50 µg desmopressin), SL 1 h before bed[3]

Women are more sensitive to the antidiuretic effect of sublingual desmopressin and had more hyponatremia at the 55.3-µg acetate dose in NOCDURNA trials, supporting the lower labeled dose for women.[3]

Guideline position. The EAU non-neurogenic female LUTS guideline (limited update March 2026) strongly recommends offering desmopressin to women with nocturia from nocturnal polyuria after counselling on hyponatremia. It also strongly recommends careful sodium monitoring in older patients and avoiding desmopressin when baseline sodium is below the normal range. A weak recommendation supports combining an anticholinergic with desmopressin in women with OAB and nocturnal polyuria.[30]

The EAU non-neurogenic male LUTS guideline (March 2026 update) weakly recommends offering desmopressin for nocturia from nocturnal polyuria in men under 65 years. It strongly recommends checking serum sodium at baseline, on day 3 and day 7, at 1 month and periodically, more often in men over 65 or at increased risk, and discussing benefit against risk. In the pooled ODT data it cites, clinically significant hyponatremia occurred in 11% of men aged 65 or older and in 0% of men under 65 at 50 mcg. Low-dose desmopressin should not be started in men aged 65 or older with a below-normal sodium. Titrated-dose trials that included men reported hyponatremia in 3.2% and serious adverse events in 1.3%.[32]

Older adults. The 2023 AGS Beers Criteria give a strong recommendation (moderate-quality evidence) to avoid desmopressin for nocturia or nocturnal polyuria in older adults because of hyponatremia risk; the 2025 AGS alternatives paper prioritizes SCREeN comorbidities, behavioral measures and treatment of concomitant OAB or BPH.[39][12] If treatment is selected after individualized risk assessment, use the specific product label and early sodium surveillance; oral and sublingual microgram doses cannot be substituted.[3][6]

2. Primary monosymptomatic nocturnal enuresis (children ≥ 6 yr)​

Desmopressin and enuresis alarms are first-line treatments.[8][13] In the DRYCHILD randomized trial, 324 treatment-naive children aged 6–14 years with primary monosymptomatic enuresis were assigned to diary-guided treatment selection or random desmopressin/alarm assignment. At eight weeks, response (at least 50% fewer wet nights) occurred in 104/141 versus 85/140 analyzed children, respectively (RR 1.21, 95% CI 1.02–1.45).[34]

Updated efficacy (Cochrane 2025). In the 2025 Cochrane review's placebo comparisons, desmopressin reduced wet nights during treatment by a mean of 1.81 per week in 16 studies (1,267 children; 95% CI 1.39–2.24 fewer; low certainty) and increased achievement of 14 consecutive dry nights by the end of treatment in 11 studies (922 children; RR 3.18, 95% CI 1.75–5.80; moderate certainty). End-of-treatment results may resemble alarm therapy, but alarms give more durable dryness after treatment. Adding an alarm to desmopressin reduced wet nights by 0.88 per week versus desmopressin alone (moderate certainty).[24]

Dosing is formulation- and jurisdiction-specific. The US DDAVP oral tablet label for children ≥6 years starts at 0.2 mg at bedtime and permits titration to 0.6 mg.[6] UK enuresis DesmoMelt starts at 120 µg and permits 240 µg; its label begins at age 5.[25] These enuresis melts are not the US NOCDURNA nocturia product and are not interchangeable tablet-for-tablet or microgram-for-microgram.[3][6][25]

Practical points.[7][8]

  • Take 1 hour before the last void before bed
  • Restrict fluids from 1 h before to 8 h after dosing
  • Effective only on the night of administration (daily use for continuous effect); can be used as needed for sleepovers or camp
  • Reassess response, timing, fluid intake and dose before declaring failure; NICE assesses response at 4 weeks. Continue an effective course for 3 months, then reassess the need for treatment with a drug holiday.[26]
  • Intranasal is no longer approved for enuresis due to high hyponatremia risk
  • The most common cause of unresponsiveness is reduced nocturnal bladder capacity, not polyuria

The International Consultation on Incontinence assigns desmopressin a Level 1, Grade A recommendation in monosymptomatic enuresis.[7]

3. Neurogenic LUTD nocturia and frequency​

Small studies describe off-label treatment of selected neurological patients with documented nocturnal polyuria:[14][15]

  • Multiple sclerosis. Most studied population; symptom relief for 6 h[14][15]
  • Parkinson's disease. Desmopressin has been described for nocturnal polyuria associated with Parkinson's disease, but a later neurological systematic review found only one Parkinson study; disease-specific benefit and safety remain uncertain.[14][15]
  • Spinal cord injury. A study of 16 patients with complete paraplegia or tetraplegia found absent day-night variation in ADH and urine output; small desmopressin studies report reduced nocturnal output.[15][16]
  • Other: multiple system atrophy, stroke, neural tube defects[15]

A systematic review of 14 studies (200 patients; 7 studies in MS; 13 of 14 used intranasal desmopressin) pooled three studies and found fewer nocturnal voids versus placebo (MD −0.75, 95% CI −1.10 to −0.41); the trials were of low to moderate quality.[15] The EAU Neuro-Urology guideline (2026) notes that optimal dosing is undefined, hyponatremia is frequent and studies are heterogeneous and low quality, and it strongly recommends screening and monitoring serum sodium when desmopressin is used for nocturnal polyuria.[31]

Selection: distinguish excess urine production from impaired bladder storage and assess fluid balance, renal function and sodium. NOCDURNA is contraindicated in heart failure and eGFR <50 mL/min/1.73 m²; it is not recommended in patients with a history of urinary retention or at risk of increased intracranial pressure.[3]

4. Perioperative hemostasis in urologic surgery​

FDA-approved for hemostasis in mild hemophilia A (factor VIII > 5%) and mild-to-moderate vWD Type I (factor VIII > 5%) during surgery. Establish responsiveness and coordinate with hematology.[5]

Dose. 0.3 µg/kg IV (max 20 µg) over 15–30 min, given 30 min before the procedure; repeat dosing, if needed, depends on the clinical and laboratory response and sodium and fluid monitoring.[5]

Tachyphylaxis. May occur with administration more often than every 48 h; the response is reproducible if given every 2–3 days.[5]

Urologic relevance.

  • In desmopressin-responsive mild hemophilia A or type 1 vWD, IV desmopressin may support a hematology-directed plan for TURP, prostatectomy, cystoscopy with biopsy, or other urologic procedures.[5][17] For major surgery in vWD, the 2021 ASH/ISTH/NHF/WFH guideline advises against desmopressin alone and conditionally suggests maintaining both VWF and factor VIII activity at ≥0.50 IU/mL for at least three postoperative days; it generally contraindicates desmopressin for surgery in type 1C vWD.[37]
  • ASA Practice Guidelines for Perioperative Blood Management note placebo-controlled meta-analytic evidence that desmopressin reduces postoperative blood loss (Category A1-B)[17]
  • US injection labeling is limited to the specified mild hemophilia A and Type I vWD populations; it is ineffective for severe classic hemophilia or factor VIII antibodies. Type 2B vWD carries thrombocytopenia or thrombosis risk; other vWD subtypes require hematology-directed treatment.[5]
  • Not standard for routine post-TURP hematuria in patients without bleeding disorders; manage bleeding according to its severity and source; any antifibrinolytic use requires a procedure-specific assessment[18]

5. Central diabetes insipidus​

Urologists may encounter transient central DI after transsphenoidal pituitary surgery or head trauma: massive polyuria with polydipsia.[6][19][20]

RouteDose
OralStart 0.05 mg BID; range 0.1–1.2 mg/day in divided doses[6]
IV / SC2–4 µg/day in 1–2 doses[5]
Intranasal10–40 µg/day[33]

Adjust to urine volume and osmolality; titrate morning and evening doses separately to preserve diurnal rhythm. Ineffective for nephrogenic DI.[6]

Hyponatremia — the dose-limiting safety concern​

The defining toxicity.[3][5] NOCDURNA and the cited injection label carry an FDA boxed warning.[3][5]

Epidemiology​

  • In a population-based cohort of adults newly prescribed an older desmopressin formulation, the rate of a primary-position hyponatremia diagnosis was 146 per 1,000 person-years versus 11 per 1,000 with oxybutynin, a 13-fold association (HR 13.19; 95% CI 6.69–26.01); when follow-up was limited to 30 days, the HR was 19.41.[21]
  • In the real-world older-male cohort, 16.7% discontinued for hyponatremia detected on routine monitoring.[11]
  • Hyponatremia (RR 5.1) and headache (RR 4.3) are the most common adverse events in meta-analysis.[10]

Risk factors[21][22]​

  • Older age and lower baseline sodium. Hyponatremia risk is higher at age ≥65 in NOCDURNA trials.[3] In Japanese postmarketing surveillance of 1,049 men with nocturnal polyuria taking 25- or 50-µg orally disintegrating desmopressin for up to 52 weeks, physician-reported hyponatremia occurred in 140 (13.3%); rates were 112/629 (17.8%) at age ≥75 versus 28/420 (6.7%) under 75, and 60/256 (23.4%) with baseline sodium 135–139 versus 51/602 (8.5%) at 140–147 mmol/L.[38]
  • Extremes of age (pediatric and geriatric)
  • Intranasal spray used for enuresis. Postmarketing reports found more hyponatremia and hyponatremic convulsions than with desmopressin tablets.[33]
  • Concurrent diuretic use (especially loop diuretics)
  • Systemic or inhaled glucocorticoids
  • Polydipsia / excessive fluid intake
  • CHF, CKD, SIADH, cystic fibrosis
  • Intercurrent illness with fluid shifts (GI illness)

Contraindications — NOCDURNA label[3]​

  • Hyponatremia or history of hyponatremia
  • Excessive fluid intake / polydipsia
  • Loop diuretics or systemic / inhaled glucocorticoids
  • Known or suspected SIADH
  • Conditions that cause fluid or electrolyte imbalance
  • Renal impairment with eGFR <50 mL/min/1.73 m²[3]
  • Heart failure or uncontrolled hypertension (the Noctiva label specified NYHA class II–IV heart failure; it also listed primary nocturnal enuresis)[23]

The DDAVP tablet and desmopressin injection labels are also contraindicated with creatinine clearance <50 mL/min and with hyponatremia or a history of it.[5][6] The current injection label adds loop diuretics, systemic or inhaled glucocorticoids, SIADH, polydipsia, heart failure and uncontrolled hypertension, and carries the boxed hyponatremia warning: sodium within 7 days and at about 1 month of starting, then periodically, more often at age 65 or older. The older-format tablet label has no boxed warning or sodium schedule; it advises fluid restriction and observation for hyponatremia symptoms. The NOCDURNA label uses the same 7-day and 1-month schedule. The 3-day check in the EAU male LUTS guideline is a guideline schedule, not a US label requirement.[3][5][6][32]

Required monitoring for nocturia formulations[3][23]​

  1. Confirm normal serum sodium before starting or resuming
  2. Recheck within 7 days of initiation or resumption; repeat after dose escalation when applicable
  3. Recheck at about 1 month
  4. Periodic monitoring thereafter
  5. More frequent monitoring in patients ≥ 65 or with risk factors
  6. Hold or stop if hyponatremia occurs

Patient counseling — symptoms of water intoxication[6]​

Headache, nausea / vomiting, weight gain, fatigue, lethargy, disorientation, muscle weakness or cramps, irritability, decreased appetite, restlessness. Severe: seizure, coma, respiratory arrest. Discontinue and call if these develop.

Fluid restriction[6][7]​

Keep fluid intake to a minimum from 1 h before through at least 8 h after dosing; for DDAVP tablets used for enuresis, the label specifies until the next morning or at least 8 h after dosing.[3][6] Suspend enuresis treatment during acute vomiting, diarrhea, fever or other circumstances requiring increased fluid intake.

Other Adverse Effects​

  • Headache (RR 4.3 versus placebo)[10]
  • Slight BP elevation (rare with oral; more common with intranasal / IV at high doses)
  • Facial flushing (with IV)
  • Nausea, abdominal cramps
  • Rare serious hypersensitivity, including anaphylaxis; review the specific product label
  • Thrombotic events have been reported with desmopressin injection, and the injection label warns of platelet aggregation and thrombosis in type 2B vWD.[5]

Drug Interactions[22]​

  • Loop diuretics, thiazides. Increase hyponatremia risk (loop diuretics are a contraindication for nocturia formulations)[3]
  • SSRIs, SNRIs, TCAs. May potentiate hyponatremia via SIADH
  • NSAIDs. May potentiate antidiuretic effect
  • Carbamazepine, chlorpromazine. May enhance antidiuretic effect
  • Glucocorticoids (systemic or inhaled). Contraindicated with nocturia formulations[3]

Practical Prescribing Summary​

IndicationFormulationDoseMonitoring
Nocturia (NP) — womenNOCDURNA SL27.7 µg acetate (=25 µg desmopressin), 1 h before bedNa⁺ at baseline, within 7 d, 1 mo, then periodic[3]
Nocturia (NP) — menNOCDURNA SL55.3 µg acetate (=50 µg desmopressin), 1 h before bedSame[3]
Nocturia — older adultsIndividualized; Beers recommends avoidance—If used, apply early label-based sodium checks, with closer monitoring for age/risk
Nocturnal enuresis (US ≥6 yr)US oral tablet; regional enuresis melts have separate labelingUS tablet 0.2 mg → 0.6 mg qhs; UK DesmoMelt 120 → 240 µg (≥5 yr)Na⁺ if symptoms; mandatory fluid restriction [6][25]
Neurogenic nocturiaNOCDURNA is labeled for adults with nocturia due to confirmed NP who awaken at least twice nightly; other regimens may be off-labelSpecialist assessment of confirmed NP and product-specific regimenApply renal/fluid contraindications and sodium monitoring [3][15]
Perioperative hemostasisIV0.3 µg/kg (max 20 µg) over 15–30 min, 30 min pre-opFactor VIII and VWF response for type 1 vWD, Na⁺, BP and pulse during infusion; tachyphylaxis may occur if given more often than every 48 h.[5]
Central DIOral / IN / IV-SCStart PO 0.05 mg BID; total 0.1–1.2 mg/day in divided doses; IV-SC 2–4 µg/day; IN 10–40 µg/dayUrine volume, osmolality, Na⁺[6][5][33]

Clinical Positioning​

  • Document nocturnal polyuria with a bladder diary (>33% of 24-h output overnight, or an age-adjusted threshold) before starting; patients without NP need cause-directed treatment (for example, storage treatment for OAB, outlet treatment for BPH, or treatment of a sleep disorder)[1][3]
  • First-line behavioral measures. Fluid restriction in the evening, leg elevation, compression stockings for dependent edema, address apnea and CHF[1]
  • Consider desmopressin when behavioral measures are inadequate and NP is confirmed, after checking baseline sodium and the chosen formulation's contraindications.[3][30][32]
  • Older adults. Beers Criteria recommend avoidance; if used, start lowest dose with rigorous sodium monitoring
  • Sodium monitoring is needed. Baseline plus 7-day plus 1-month plus periodic sodium monitoring is the standard

See Also​

References​

1. Weiss JP, Everaert K. "Management of nocturia and nocturnal polyuria." Urology. 2019;133S:24–33. doi:10.1016/j.urology.2019.09.022

2. Chung E. "Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia." Expert Opin Pharmacother. 2018;19(3):291–298. doi:10.1080/14656566.2018.1429406

3. NOCDURNA (desmopressin acetate) sublingual tablets: US prescribing information. DailyMed label updated October 19, 2023. Official label. Accessed September 11, 2026.

4. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. "Desmopressin for treating nocturia in men." Cochrane Database Syst Rev. 2017;10:CD012059. doi:10.1002/14651858.CD012059.pub2

5. Desmopressin acetate injection: US prescribing information. DailyMed, 2025 label. Official label.

6. DDAVP (desmopressin acetate) tablets: US prescribing information. DailyMed label version of December 10, 2025. Official label.

7. Vande Walle J, Rittig S, Bauer S, et al. "Practical consensus guidelines for the management of enuresis." Eur J Pediatr. 2012;171(6):971–983. doi:10.1007/s00431-012-1687-7

8. Robson WL. "Evaluation and management of enuresis." N Engl J Med. 2009;360(14):1429–1436. doi:10.1056/NEJMcp0808009

9. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. "Desmopressin for treating nocturia in men." BJU Int. 2018;122(4):549–559. doi:10.1111/bju.14183

10. Ebell MH, Radke T, Gardner J. "A systematic review of the efficacy and safety of desmopressin for nocturia in adults." J Urol. 2014;192(3):829–835. doi:10.1016/j.juro.2014.03.095

11. Chu C, Lin CC. "Real-world safety and effectiveness of an initial 0.1 mg dose of desmopressin in older men with nocturnal polyuria." J Urol. 2026. doi:10.1097/JU.0000000000005003

12. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria®." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

13. Lauters RA, Garcia KW, Arnold JJ. "Enuresis in children: common questions and answers." Am Fam Physician. 2022;106(5):549–556. PMID 36379501

14. Panicker JN, Fowler CJ, Kessler TM. "Lower urinary tract dysfunction in the neurological patient: clinical assessment and management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8

15. Hajebrahimi S, Darvishi A, HajEbrahimi R, et al. "Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: a systematic review and meta-analysis." Neurourol Urodyn. 2024;43(1):167–182. doi:10.1002/nau.25291

16. Kilinç S, Akman MN, Levendoglu F, Ozker R. "Diurnal variation of antidiuretic hormone and urinary output in spinal cord injury." Spinal Cord. 1999;37(5):332–335. doi:10.1038/sj.sc.3100814

17. American Society of Anesthesiologists Task Force on Perioperative Blood Management. "Practice guidelines for perioperative blood management." Anesthesiology. 2015;122(2):241–275. doi:10.1097/ALN.0000000000000463

18. Te AE, Te AG, Ramaswamy A, Kaplan SA. "Practical management of hematuria after endoscopic surgery for benign prostatic obstruction." Prostate Cancer Prostatic Dis. 2026. doi:10.1038/s41391-026-01111-w

19. Angelousi A, Alexandraki KI, Mytareli C, Grossman AB, Kaltsas G. "New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance)." J Neuroendocrinol. 2023;35(1):e13233. doi:10.1111/jne.13233

20. Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ. "Diagnosis and management of central diabetes insipidus in adults." J Clin Endocrinol Metab. 2022;107(10):2701–2715. doi:10.1210/clinem/dgac381

21. Fralick M, Schneeweiss S, Wallis CJD, Jung EH, Kesselheim AS. "Desmopressin and the risk of hyponatremia: a population-based cohort study." PLoS Med. 2019;16(10):e1002930. doi:10.1371/journal.pmed.1002930

22. Chin X, Teo SW, Lim ST, et al. "Desmopressin therapy in children and adults: pharmacological considerations and clinical implications." Eur J Clin Pharmacol. 2022;78(6):907–917. doi:10.1007/s00228-022-03297-z

23. US Food and Drug Administration. NOCTIVA (desmopressin acetate) nasal spray: prescribing information. 2017 approval label, sections 2–5. FDA label. Historical formulation information; this citation does not establish current commercial availability.

24. Hahn D, Stewart F, Raman G. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2025;7:CD002112. doi:10.1002/14651858.CD002112.pub2. Review summary.

25. Ferring Pharmaceuticals. DesmoMelt 120/240 micrograms oral lyophilisate: UK Summary of Product Characteristics. SmPC. Accessed September 12, 2026.

26. NICE. Bedwetting in under 19s (CG111): recommendations, desmopressin treatment. Guideline. Accessed September 12, 2026.

27. Drugs.com. Nocdurna (desmopressin acetate) sublingual tablets: prescribing information and status notice (Antares/Ferring license terminated October 19, 2023). Drugs.com. Accessed September 24, 2026.

28. Ferring Pharmaceuticals. Noqdirna 25 micrograms oral lyophilisate: UK Summary of Product Characteristics. SmPC. Accessed September 24, 2026.

29. OINDPnews. "Avadel Pharmaceuticals drops Noctiva nasal spray." 2019. Article.

30. European Association of Urology. Management of non-neurogenic female lower urinary tract symptoms (LUTS): limited update March 2026. Section 4.6.4 (pharmacological treatment of nocturia).

31. European Association of Urology. Neuro-Urology guidelines, 2026 edition. Sections on desmopressin for nocturnal polyuria in neurological patients.

32. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male LUTS. 2026 (March update). Official full guideline. See section 5.5.3.a.

33. Oceanside Pharmaceuticals. Desmopressin nasal spray solution: US prescribing information. Revised May 2025. DailyMed label.

34. Jørgensen CS, Dossche L, Zhai R, et al. "Development of a Novel Prediction Tool for Response to First-Line Treatments of Monosymptomatic Nocturnal Enuresis: A Randomized, Controlled, International, Multicenter Study (DRYCHILD)." J Urol. 2024;212(4):539–549. doi:10.1097/JU.0000000000004129

35. Kottke D, Burckhardt BB, Knaab TC, et al. "Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration." Int J Pharm X. 2021;3:100082. doi:10.1016/j.ijpx.2021.100082

36. U.S. Food and Drug Administration. CY 2018 CDER Drug and Biologic Calendar Year Approvals. 2018. FDA approval list.

37. Connell NT, Flood VH, Brignardello-Petersen R, et al. "ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease." Blood Adv. 2021;5(1):301–325. doi:10.1182/bloodadvances.2020003264

38. Ogawa Y, Kuramoto K, Nakano A. "Long-term safety of desmopressin orally disintegrating tablets in men with nocturia due to nocturnal polyuria: final results of a specified drug use-results survey in Japan." Low Urin Tract Symptoms. 2026;18(2):e70052. doi:10.1111/luts.70052

39. 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. "American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults." J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372